Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.54 |
| ▸ | MTOR | P42345 | 1/20 | 0.54 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.46 |
| ▸ | CETP | P11597 | 3/20 | 0.43 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ALPG | P10696 | 1/20 | 0.39 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | ITPR3 | Q14573 | 3/20 | 0.38 |
| ▸ | ITPR2 | Q14571 | 2/20 | 0.38 |
| ▸ | ITPR1 | Q14643 | 2/20 | 0.38 |
| ▸ | INPP5A | Q14642 | 1/20 | 0.38 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9874266 | 0.95 | TSHR (0.53) | TSHRPDPK1MTORFUCA1CETP | |
| SCHEMBL13109573 | 0.91 | PDPK1 (0.65) | TSHRPDPK1MTORFUCA1CETP | |
| SCHEMBL5830234 | 0.91 | PDPK1 (0.65) | TSHRPDPK1MTORFUCA1CETP | |
| SCHEMBL9874053 | 0.89 | PDPK1 (0.63) | TSHRPDPK1MTORFUCA1CETP | |
| SCHEMBL13109619 | 0.89 | PDPK1 (0.68) | TSHRPDPK1MTORFUCA1CETP | |
| SCHEMBL4340900 | 0.89 | PDPK1 (0.61) | TSHRPDPK1MTORFUCA1CETP | |
| SCHEMBL4345266 | 0.89 | PDPK1 (0.61) | TSHRPDPK1MTORFUCA1CETP | |
| SCHEMBL7720528 | 0.87 | PDPK1 (0.65) | TSHRPDPK1MTORFUCA1CETP | |
| SCHEMBL9872299 | 0.87 | PDPK1 (0.46) | TSHRPDPK1MTORFUCA1CETP | |
| SCHEMBL14094690 | 0.83 | PDPK1 (0.73) | TSHRPDPK1MTORFUCA1CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210361680-A1 | INOSITOL-BASED IMMUNOTHERAPIES | NORMOXYS INC (US) | 2021-11-25 | — | — | US | disclosed |
| EP-3787634-A1 | INOSITOL-BASED IMMUNOTHERAPIES | NormOxys, Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20160067267-A1 | MYO-INOSITOL TRISPYROPHOSPHATE AS AN ANTI-OBESITY AGENT | NORMOXYS, INC. (US) | 2016-03-10 | — | — | US | disclosed |
| EP-2968617-A1 | MYO-INOSITOL TRISPYROPHOSPHATE AS AN ANTI-OBESITY AGENT | NormOxys, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2015138916-A1 | MYO-INOSITOL TRISPYROPHOSHATE AS AN ANTI-DIABETIC AGENT | NICOLAU YVES CLAUDE (US) | 2015-09-17 | — | — | WO | disclosed |
| WO-2014143939-A1 | MYO-INOSITOL TRISPYROPHOSPHATE AS AN ANTI-OBESITY AGENT | NORMOXYS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140171394-A1 | CYCLITOLS AND THEIR DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | UNIVERSITE DE STRASBOURG (FR) | 2014-06-19 | — | — | US | disclosed |
| US-20130190524-A1 | CYCLITOLS AND THEIR DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | UNIVERSITE DE STRASBOURG (FR) | 2013-07-25 | — | — | US | disclosed |
| US-20080200437-A1 | Polyphosphorylated inositol derivatives; allosteric effectors, cell signaling molecule analogs; hypoxia related diseases | UNIVERSITE DE STRASBOURG (FR) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200437-A1 | Polyphosphorylated inositol derivatives; allosteric effectors, cell signaling molecule analogs; hypoxia related diseases | PPIP5K2, IP6K1, IP6K3 | TSHR 2294/4885PDPK1 29/4885MTOR 122/4885 |
| US-20130190524-A1 | CYCLITOLS AND THEIR DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | PPIP5K2, ITPA, IPMK | TSHR 1898/4885PDPK1 55/4885MTOR 272/4885 |
| US-20140171394-A1 | CYCLITOLS AND THEIR DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | PPIP5K2, ITPA, IPMK | TSHR 1898/4885PDPK1 55/4885MTOR 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.